Brief: Alteogen Receives Positive CHMP Opinion For Aflibercept Biosimilar, 'EYLUXVI® (ALT-L9)'
28/07/2025 07:32
July 28 (Reuters) - Alteogen Inc 196170.KQ: ALTEOGEN RECEIVES POSITIVE CHMP OPINION FOR AFLIBERCEPT BIOSIMILAR, 'EYLUXVI® (ALT-L9)' Source text: ID:nPn9640nCa Further company coverage: 196170.KQ ((Reuters.Briefs@thomsonreuters.com))
Recent news on Alteogen
See all newsDeals of the day-Mergers and acquisitions
Novartis signs deal worth up to $3.2 billion for Alteogen's drug delivery technology
Brief: Alteogen To Invest 253 Billion Won In Construction Of New Factory
Brief: Alteogen Q2 Operating. Profit 34.2 Billion Won
Brief: Alteogen - Signs Exclusive License Agreement For Alt-B4 Recombinant Human Hyaluronidase